Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Increased IgE+ B Cells in Sputum, but Not Blood, Bone Marrow, or Tonsils, after Inhaled Allergen Challenge in Subjects with Asthma.

Oliveria JP, Salter BM, MacLean J, Kotwal S, Smith A, Harris JM, Scheerens H, Sehmi R, Gauvreau GM.

Am J Respir Crit Care Med. 2017 Jul 1;196(1):107-109. doi: 10.1164/rccm.201611-2274LE. No abstract available.

PMID:
28665197
2.

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.

Wang X, Barbosa J, Blomgren P, Bremer MC, Chen J, Crawford JJ, Deng W, Dong L, Eigenbrot C, Gallion S, Hau J, Hu H, Johnson AR, Katewa A, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, DiPaolo J, Reif K, Scheerens H, Schmitt A, Wong H, Xiong JM, Xu J, Zhao Z, Zhou F, Currie KS, Young WB.

ACS Med Chem Lett. 2017 May 3;8(6):608-613. doi: 10.1021/acsmedchemlett.7b00103. eCollection 2017 Jun 8.

3.

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.

Scheerens H, Malong A, Bassett K, Boyd Z, Gupta V, Harris J, Mesick C, Simnett S, Stevens H, Gilbert H, Risser P, Kalamegham R, Jordan J, Engel J, Chen S, Essioux L, Williams JA.

Clin Transl Sci. 2017 Mar;10(2):84-92. doi: 10.1111/cts.12455. Epub 2017 Feb 27.

4.

A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.

Harris JM, Cabanski CR, Scheerens H, Samineni D, Bradley MS, Cochran C, Staubach P, Metz M, Sussman G, Maurer M.

J Allergy Clin Immunol. 2016 Dec;138(6):1730-1732. doi: 10.1016/j.jaci.2016.06.023. Epub 2016 Jul 19. No abstract available.

PMID:
27567329
5.

Peripheral blood gene expression predicts clinical benefit from anti-IL-13 in asthma.

Choy DF, Jia G, Abbas AR, Morshead KB, Lewin-Koh N, Dua R, Rivera P, Moonsamy P, Fontecha M, Balasubramanyam A, Santini C, Bassett E, Ray JM, Cabanski CR, Bradley MS, Maciuca R, Mosesova S, Scheerens H, Arron JR.

J Allergy Clin Immunol. 2016 Oct;138(4):1230-1233.e8. doi: 10.1016/j.jaci.2016.06.008. Epub 2016 Jun 29. No abstract available.

PMID:
27474124
6.

A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.

Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG.

Respir Res. 2016 Mar 18;17:29. doi: 10.1186/s12931-016-0347-2.

7.

Bioanalytical challenges and improved detection of circulating levels of IL-13.

Cai F, Hornauer H, Peng K, Schofield CA, Scheerens H, Morimoto AM.

Bioanalysis. 2016 Feb;8(4):323-32. doi: 10.4155/bio.15.254. Epub 2016 Feb 5.

PMID:
26847873
8.

Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.

Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Eigenbrot C, Gallion S, Johnson AR, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, Di Paolo J, Reif K, Scheerens H, Schmitt A, Wang X, Wong H, Xiong JM, Xu J, Yu C, Zhao Z, Currie KS.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):575-9. doi: 10.1016/j.bmcl.2015.11.076. Epub 2015 Nov 24.

PMID:
26675441
9.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K.

Thorax. 2015 Aug;70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719. Epub 2015 May 22.

10.

Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.

Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Gallion S, Hymowitz SG, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Maurer B, Mitchell SA, Ortwine DF, Di Paolo J, Reif K, Scheerens H, Schmitt A, Sowell CG, Wang X, Wong H, Xiong JM, Xu J, Zhao Z, Currie KS.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1333-7. doi: 10.1016/j.bmcl.2015.01.032. Epub 2015 Feb 7.

PMID:
25701252
11.

Targeting IgE production in mice and humans.

Wu LC, Scheerens H.

Curr Opin Immunol. 2014 Dec;31:8-15. doi: 10.1016/j.coi.2014.08.001. Epub 2014 Aug 25. Review.

12.

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.

Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM.

Sci Transl Med. 2014 Jul 2;6(243):243ra85. doi: 10.1126/scitranslmed.3008961.

13.

Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.

Arron JR, Choy DF, Scheerens H, Matthews JG.

Ann Am Thorac Soc. 2013 Dec;10 Suppl:S206-13. doi: 10.1513/AnnalsATS.201303-047AW. Review.

PMID:
24313774
14.

OX40L blockade and allergen-induced airway responses in subjects with mild asthma.

Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, Laviolette M, Killian KJ, Davis BE, Larché M, Kipling C, Dua B, Mosesova S, Putnam W, Zheng Y, Scheerens H, McClintock D, Matthews JG, O'Byrne PM.

Clin Exp Allergy. 2014 Jan;44(1):29-37. doi: 10.1111/cea.12235.

15.

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG.

Clin Exp Allergy. 2014 Jan;44(1):38-46. doi: 10.1111/cea.12220.

16.

Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Spiess C, Bevers J 3rd, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, Scheer JM, Giese G, Persson J, Zhang Y, Dennis MS, Giulianotti J, Gupta P, Reilly D, Palma E, Wang J, Stefanich E, Scheerens H, Fuh G, Wu LC.

J Biol Chem. 2013 Sep 13;288(37):26583-93. doi: 10.1074/jbc.M113.480483. Epub 2013 Jul 23.

17.

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.

Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG.

J Allergy Clin Immunol. 2013 Sep;132(3):567-574.e12. doi: 10.1016/j.jaci.2013.03.051. Epub 2013 May 29.

PMID:
23726041
18.

Redefining approaches to asthma: developing targeted biologic therapies.

Arron JR, Scheerens H, Matthews JG.

Adv Pharmacol. 2013;66:1-49. doi: 10.1016/B978-0-12-404717-4.00001-9. Review.

PMID:
23433454
19.

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.

Scheerens H, Su Z, Irving B, Townsend MJ, Zheng Y, Stefanich E, Chindalore V, Bingham CO 3rd, Davis JC Jr.

Arthritis Res Ther. 2011;13(5):R177. doi: 10.1186/ar3502. Epub 2011 Oct 26.

20.

Lebrikizumab treatment in adults with asthma.

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG.

N Engl J Med. 2011 Sep 22;365(12):1088-98. doi: 10.1056/NEJMoa1106469. Epub 2011 Aug 3.

Supplemental Content

Loading ...
Support Center